+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Amifostine Market - Global Forecast 2026-2032- Product Image
Amifostine Market - Global Forecast 2026-2032- Product Image
New

Amifostine Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6014936
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The amifostine market is positioned for sustained growth as supportive oncology care expands, driven by increased focus on toxicity mitigation, evolving care settings, and heightened scrutiny around cost-effectiveness and real-world safety. Strategic adoption depends on aligning clinical evidence, supply chain agility, and multidisciplinary operational readiness.

Market Snapshot: Amifostine Market Growth and Dynamics

The amifostine market is demonstrating consistent expansion, increasing from USD 588.46 million in 2025 to USD 642.66 million in 2026, and projected to reach USD 1.11 billion by 2032 with a CAGR of 9.57%. This growth is tied to rising demand for effective cytoprotective agents in modern oncology, reflecting shifts in treatment paradigms, decentralized care delivery, and evolving payer demands for robust, value-based solutions.

Scope & Segmentation

  • Clinical Indications: Head and neck cancer, lung cancer, and prostate cancer are the primary focus, each presenting unique toxicity profiles and therapeutic considerations for amifostine integration.
  • Therapy Applications: Chemotherapy, combination therapies, and radiotherapy regimens drive diverse application timing and monitoring standards.
  • End User Types: Hospitals, cancer clinics, ambulatory care centers, and home healthcare providers, each with distinct staffing needs and operating protocols.
  • Distribution Channels: Direct tender, hospital pharmacy, online pharmacy, and retail pharmacy, impacting procurement pathways and access timelines.
  • Routes of Administration: Intravenous, intramuscular, and subcutaneous delivery formats, influencing resource allocation and adverse event monitoring.
  • Geographies: Coverage spans the Americas, Europe, Middle East & Africa, and Asia-Pacific, accounting for local regulatory, infrastructure, and market access differences.
  • Dose Regimens: Standard, high, and low-dose strategies tailored to clinical protocols, comorbidities, and institutional policies.

Key Takeaways for Senior Decision-Makers

  • Integrating amifostine as part of supportive oncology pathways helps optimize patient outcomes and resource utilization by addressing dose-limiting toxicities without disrupting therapeutic intensity.
  • Stakeholder alignment among oncology, pharmacy, nursing, and procurement teams is critical to create effective administration workflows, given varying care settings and distribution models.
  • Emerging trends toward ambulatory and home-based oncology care increase the need for scalable, safe, and efficient administration protocols supported by targeted training and monitoring resources.
  • Supplier reliability and multi-sourcing strategies have grown more important due to recent trade policies and tariff adjustments that impact continuity of supply and procurement timelines.
  • Regional variations in regulatory frameworks, health system infrastructure, and payer models substantially influence both adoption speed and operational pathways for supportive therapies in different global markets.
  • Strategic partnerships that bridge clinical research, specialty distribution, and pharmacy practice drive successful uptake, enabling integration of real-world data and workflow optimization.

Tariff Impact: Supply Chain and Procurement Considerations

Recent tariff changes in the United States have triggered operational adjustments across the supply chain for oncology supportive therapies. These include import duty fluctuations, new logistical routes, and enhanced customs compliance. Manufacturers and distributors are responding by diversifying manufacturing locations, pursuing nearshoring, and implementing multi-sourcing, all of which protect against unpredictability in tariffs and imports. For hospital pharmacies and clinics, flexible administration protocols and coordinated contingency planning are now essential to maintain uninterrupted patient access and uphold quality standards for parenteral product handling.

Methodology & Data Sources

The report utilizes a mixed methods approach combining peer-reviewed clinical literature, guidelines from oncology societies, in-depth interviews with clinical and pharmacy stakeholders, and supply chain analyses. This triangulated methodology ensures both qualitative and quantitative accuracy, focusing on contemporary clinical protocols and practical consideration of administrative, regulatory, and regional data limitations.

Why This Report Matters

  • Provides actionable insights for aligning clinical, operational, and procurement strategies in oncology supportive care, supporting evidence-based formulary decisions.
  • Enables senior leaders to anticipate and respond to supply chain risks by highlighting the implications of tariff policies and decentralized care delivery on procurement and logistics.
  • Supports real-world implementation by offering segmentation frameworks that facilitate tailored dosing and administration strategies, ensuring quality care across diverse settings.

Conclusion

Effective deployment of amifostine in oncology care requires multidisciplinary coordination, robust evidence alignment, and continuous supply chain vigilance. Senior decision-makers gain value by integrating clinical insights, operational best practices, and supply resilience to maintain quality patient care.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Amifostine Market, by Route Of Administration
8.1. Intramuscular
8.2. Intravenous
8.3. Subcutaneous
9. Amifostine Market, by Indication
9.1. Head And Neck Cancer
9.2. Lung Cancer
9.3. Prostate Cancer
10. Amifostine Market, by Dose Regimen
10.1. High Dose
10.2. Low Dose
10.3. Standard Dose
11. Amifostine Market, by Application
11.1. Chemotherapy
11.2. Combination Therapy
11.3. Radiotherapy
12. Amifostine Market, by End User
12.1. Ambulatory Care Centers
12.2. Cancer Clinics
12.3. Home Healthcare
12.4. Hospitals
13. Amifostine Market, by Distribution Channel
13.1. Direct Tender
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Amifostine Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Amifostine Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Amifostine Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Amifostine Market
18. China Amifostine Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Accord Healthcare Ltd
19.6. Albemarle Corporation
19.7. Alkem Laboratories Ltd
19.8. Apotex Inc
19.9. Aurobindo Pharma Limited
19.10. Cipla Limited
19.11. Clinigen Group plc
19.12. Dr. Reddy’s Laboratories Ltd
19.13. Fresenius SE & Co. KGaA
19.14. Glenmark Pharmaceuticals Ltd
19.15. Harbin Pharmaceutical Group Co., Ltd
19.16. Hetero Labs Limited
19.17. Hikma Pharmaceuticals plc
19.18. Jiangsu Hengrui Medicine Co., Ltd
19.19. Lannett Company Inc
19.20. Mylan N.V.
19.21. Natco Pharma Limited
19.22. Sandoz AG
19.23. Shandong Qilu Pharmaceutical Co., Ltd
19.24. Shanghai Fosun Pharmaceutical (Group) Co., Ltd
19.25. Sun Pharmaceutical Industries Limited
19.26. Teva Pharmaceutical Industries Ltd
19.27. Torrent Pharmaceuticals Ltd
19.28. Wockhardt Ltd
19.29. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL AMIFOSTINE MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL AMIFOSTINE MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL AMIFOSTINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL AMIFOSTINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL AMIFOSTINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL AMIFOSTINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL AMIFOSTINE MARKET SIZE, BY HEAD AND NECK CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL AMIFOSTINE MARKET SIZE, BY HEAD AND NECK CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL AMIFOSTINE MARKET SIZE, BY HEAD AND NECK CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL AMIFOSTINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL AMIFOSTINE MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL AMIFOSTINE MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL AMIFOSTINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL AMIFOSTINE MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL AMIFOSTINE MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL AMIFOSTINE MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL AMIFOSTINE MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL AMIFOSTINE MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL AMIFOSTINE MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL AMIFOSTINE MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL AMIFOSTINE MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL AMIFOSTINE MARKET SIZE, BY STANDARD DOSE, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL AMIFOSTINE MARKET SIZE, BY STANDARD DOSE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL AMIFOSTINE MARKET SIZE, BY STANDARD DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL AMIFOSTINE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL AMIFOSTINE MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL AMIFOSTINE MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL AMIFOSTINE MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL AMIFOSTINE MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL AMIFOSTINE MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL AMIFOSTINE MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL AMIFOSTINE MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL AMIFOSTINE MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL AMIFOSTINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL AMIFOSTINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL AMIFOSTINE MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL AMIFOSTINE MARKET SIZE, BY CANCER CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL AMIFOSTINE MARKET SIZE, BY CANCER CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL AMIFOSTINE MARKET SIZE, BY CANCER CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL AMIFOSTINE MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL AMIFOSTINE MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL AMIFOSTINE MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL AMIFOSTINE MARKET SIZE, BY DIRECT TENDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL AMIFOSTINE MARKET SIZE, BY DIRECT TENDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL AMIFOSTINE MARKET SIZE, BY DIRECT TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL AMIFOSTINE MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL AMIFOSTINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL AMIFOSTINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL AMIFOSTINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL AMIFOSTINE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL AMIFOSTINE MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL AMIFOSTINE MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL AMIFOSTINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. AMERICAS AMIFOSTINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 70. AMERICAS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 71. AMERICAS AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 72. AMERICAS AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 73. AMERICAS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 74. AMERICAS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 75. AMERICAS AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 76. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 78. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 79. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 80. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 81. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 82. NORTH AMERICA AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 83. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 84. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 86. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 87. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 88. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. LATIN AMERICA AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 90. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 91. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. EUROPE AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. EUROPE AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 99. EUROPE AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 100. EUROPE AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 101. EUROPE AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 102. EUROPE AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 103. EUROPE AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 104. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 105. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 106. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 108. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 109. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. MIDDLE EAST AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. AFRICA AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 112. AFRICA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 113. AFRICA AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 114. AFRICA AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 115. AFRICA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 116. AFRICA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 117. AFRICA AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 118. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. GLOBAL AMIFOSTINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 126. ASEAN AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 127. ASEAN AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. ASEAN AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 129. ASEAN AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 130. ASEAN AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 131. ASEAN AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 132. ASEAN AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 133. GCC AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 134. GCC AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135. GCC AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 136. GCC AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 137. GCC AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 138. GCC AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. GCC AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 147. BRICS AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 148. BRICS AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 149. BRICS AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 150. BRICS AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 151. BRICS AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 152. BRICS AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 153. BRICS AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 154. G7 AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 155. G7 AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 156. G7 AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. G7 AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 158. G7 AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 159. G7 AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. G7 AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. NATO AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 162. NATO AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 163. NATO AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 164. NATO AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 165. NATO AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 166. NATO AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. NATO AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. GLOBAL AMIFOSTINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 169. UNITED STATES AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 170. UNITED STATES AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. UNITED STATES AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 172. UNITED STATES AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 173. UNITED STATES AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 174. UNITED STATES AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 175. UNITED STATES AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. CHINA AMIFOSTINE MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 177. CHINA AMIFOSTINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. CHINA AMIFOSTINE MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 179. CHINA AMIFOSTINE MARKET SIZE, BY DOSE REGIMEN, 2018-2032 (USD MILLION)
TABLE 180. CHINA AMIFOSTINE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
TABLE 181. CHINA AMIFOSTINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. CHINA AMIFOSTINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Amifostine market report include:
  • Accord Healthcare Ltd
  • Albemarle Corporation
  • Alkem Laboratories Ltd
  • Apotex Inc
  • Aurobindo Pharma Limited
  • Cipla Limited
  • Clinigen Group plc
  • Dr. Reddy’s Laboratories Ltd
  • Fresenius SE & Co. KGaA
  • Glenmark Pharmaceuticals Ltd
  • Harbin Pharmaceutical Group Co., Ltd
  • Hetero Labs Limited
  • Hikma Pharmaceuticals plc
  • Jiangsu Hengrui Medicine Co., Ltd
  • Lannett Company Inc
  • Mylan N.V.
  • Natco Pharma Limited
  • Sandoz AG
  • Shandong Qilu Pharmaceutical Co., Ltd
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd
  • Torrent Pharmaceuticals Ltd
  • Wockhardt Ltd
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 642.66 Million
Forecasted Market Value ( USD ) by 2032 $ 1110 Million
Compound Annual Growth Rate9.5%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Amifostine (CAS 20537-88-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029 - Product Image

Amifostine (CAS 20537-88-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029

  • Report
  • 50 Pages
  • Global
From
Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032 - Product Image

Extensive Stage Small Cell Lung Cancer Market - Global Forecast 2026-2032

  • Report
  • 195 Pages
  • Global
From
Doxorubicin Market - Global Forecast 2026-2032 - Product Image

Doxorubicin Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Gemcitabine HCl Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Gemcitabine HCl Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Lung Cancer Therapy - Global Strategic Business Report - Product Image

Lung Cancer Therapy - Global Strategic Business Report

  • Report
  • 368 Pages
  • Global
From

About the Market

Amifostine is a drug used in the treatment of lung cancer. It is a prodrug, meaning it is converted into an active form in the body. It works by protecting healthy cells from the toxic effects of chemotherapy and radiation therapy. It is administered intravenously and is usually given prior to radiation therapy. It is also used to reduce the risk of kidney damage caused by certain chemotherapy drugs. Amifostine is approved by the US Food and Drug Administration (FDA) for the reduction of kidney damage caused by certain chemotherapy drugs. It is also approved for the protection of healthy cells from the toxic effects of radiation therapy. The market for Amifostine is mainly driven by the increasing prevalence of lung cancer and the growing demand for effective treatments. The increasing awareness of the drug’s benefits is also driving the market. Some of the major companies in the Amifostine market include Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, and Sanofi. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.